(ARCHIVE) KaloBios Pharmaceuticals names Ted Love, Chairman of the Board of Directors

– USA, CA – KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced that the company’s board of directors has elected Ted W. Love, M.D., as the Chairman, effective May 1, 2014.  Dr. Love succeedsJames I. Healy, M.D., Ph.D., who had served as a member of the board of directors and as chairman of the board since 2001.  Dr. Healy recently informed KaloBios that in light of the company’s public offering in 2013 and his other present and potential public company board commitments, he did not intend to stand for re-election to the KaloBios board of directors at the upcoming annual meeting of stockholders, scheduled for June 18, 2014.

Dr. Love has been a member of the board of directors since March 2009. He has held senior executive and management positions at a number of biopharmaceutical companies including Onyx Pharmaceuticals, Inc., Nuvelo, Inc., Theravance, Inc. and Genentech, Inc. Dr. Love also serves or has served as a member of the boards of directors of biopharmaceutical companies Santarus, Inc., Amicus, Inc., Adventrx, Inc., Affymax, Inc. and BioRad, Inc. and serves on the board of directors of Stanford Hospital & Clinics.

“Jim has been an invaluable member of the KaloBios board of directors for nearly 13 years, and we are deeply indebted to him for his support and guidance during that time,” said David Pritchard, President and Chief Executive Officer of KaloBios. “We are extremely fortunate to have someone with Ted’s depth of clinical development expertise and leadership experience to step into the Chairman role given Jim’s transition.”

About KaloBios

KaloBios Pharmaceuticals, Inc. is developing a portfolio of proprietary, patient-targeted, first-in-class monoclonal antibodies designed to treat severe life-threatening or debilitating diseases for which there is an unmet medical need, with a clinical focus on severe respiratory diseases and cancer.

All of the company’s antibodies were generated using its proprietary Humaneered® technology, a method that converts nonhuman antibodies (typically mouse) into recombinant antibodies that have a high binding affinity to their target and are designed for chronic therapeutic use. The company believes that antibodies produced using its Humaneered® technology offer important clinical and economic advantages over antibodies generated by other methods in terms of high binding affinity, high manufacturing yields, and minimal to no immunogenicity (inappropriate immune response) upon repeat administration in humans.

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.